Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
https://finance.yahoo.com/news/tetraphase-pha...00120.html
WATERTOWN, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced four poster presentations at the American Society for Microbiology (ASM) Microbe 2018 Annual Meeting, taking place June 7-11 in Atlanta, GA. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is currently under review by the United States Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, its second-generation candidate to target MDR Gram-negative bacteria, which is currently in Phase 1 clinical testing.
The details for the data presentations at ASM are as follows:
Eravacycline poster presentations
Poster title: Microbiological Efficacy of Eravacycline Against Enterobacteriaceae and Acinetobacter, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 629
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
Poster Title: In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant Isolates, Collected Globally in 2016
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 630
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
Poster title: Eravacycline In Vitro Activity Against Clinical Isolates Obtained in the U.S. in 2016 from Urinary and Gastrointestinal Sources, Including Drug-resistant Pathogens
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 631
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
TP-6076 poster presentation
Poster title: TP-6076 is Active Against Bacterial Isolates Carrying Emergent Resistance Types
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 655
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
Additional activity:
Tetraphase will have a medical information booth set up throughout the ASM Microbe Conference.
Booth number: 3221
Booth hours: Friday, June 8 from 10:30 a.m. – 5.00 p.m.; Saturday, June 9 from 10:30 a.m. – 5:00 p.m.; and Sunday, June 10 from 10:00 a.m. – 4:00 p.m.
Additional mentions:
Poster title: A Multi-Site Study Comparing A Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Eravacycline Using Fastidious Organisms
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 209
Session information: 219 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Positive and Fastidious Bacteria
Poster title: A Multi-Site Study Comparing A Commercially Prepared Dried MIC Susceptibility System to the CLSI/ISO Broth Microdilution Method for Eravacycline Using Gram-Positive and Gram-Negative Non-Fastidious Organisms
Date and time: Friday, June 8 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 242
Session information: 042 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Negative Bacteria
Poster title: Development of Eravacycline MIC Assay for Gram-Negative Bacteria on Microscan Dried Gram-Negative MIC Panels
Date and time: Friday, June 8 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 235
Session information: 042 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Negative Bacteria
https://finance.yahoo.com/news/tetraphase-pha...00120.html
WATERTOWN, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced four poster presentations at the American Society for Microbiology (ASM) Microbe 2018 Annual Meeting, taking place June 7-11 in Atlanta, GA. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is currently under review by the United States Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, its second-generation candidate to target MDR Gram-negative bacteria, which is currently in Phase 1 clinical testing.
The details for the data presentations at ASM are as follows:
Eravacycline poster presentations
Poster title: Microbiological Efficacy of Eravacycline Against Enterobacteriaceae and Acinetobacter, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 629
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
Poster Title: In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant Isolates, Collected Globally in 2016
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 630
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
Poster title: Eravacycline In Vitro Activity Against Clinical Isolates Obtained in the U.S. in 2016 from Urinary and Gastrointestinal Sources, Including Drug-resistant Pathogens
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 631
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
TP-6076 poster presentation
Poster title: TP-6076 is Active Against Bacterial Isolates Carrying Emergent Resistance Types
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 655
Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval
Additional activity:
Tetraphase will have a medical information booth set up throughout the ASM Microbe Conference.
Booth number: 3221
Booth hours: Friday, June 8 from 10:30 a.m. – 5.00 p.m.; Saturday, June 9 from 10:30 a.m. – 5:00 p.m.; and Sunday, June 10 from 10:00 a.m. – 4:00 p.m.
Additional mentions:
Poster title: A Multi-Site Study Comparing A Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Eravacycline Using Fastidious Organisms
Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 209
Session information: 219 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Positive and Fastidious Bacteria
Poster title: A Multi-Site Study Comparing A Commercially Prepared Dried MIC Susceptibility System to the CLSI/ISO Broth Microdilution Method for Eravacycline Using Gram-Positive and Gram-Negative Non-Fastidious Organisms
Date and time: Friday, June 8 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 242
Session information: 042 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Negative Bacteria
Poster title: Development of Eravacycline MIC Assay for Gram-Negative Bacteria on Microscan Dried Gram-Negative MIC Panels
Date and time: Friday, June 8 from 11:00 a.m. – 1:00 p.m. ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Poster number: 235
Session information: 042 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Negative Bacteria
Tetraphase Pharmaceuticals Inc. (TTPH) Stock Research Links
Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
